Aura Biosciences, Inc. AURA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -73.5%-27.5pp | -46%-9.7pp | -36.3%-2.5pp | -33.8%— | |
| Return on assets | -60.3%-20.6pp | -39.7%-7.8pp | -31.9%-1.3pp | -30.6%+8.1pp | |
| Return on invested capital | -96.5%-40.5pp | -56%+0.8pp | -56.8%+64.9pp | -121.7%— | |
| Liquidity | |||||
| Current ratio | 8.1×-2.6× | 10.8×-8.0× | 18.8×-0.1× | 18.8×-2.1× | |
| Quick ratio | 8.1×-2.6× | 10.8×-8.0× | 18.8×-0.1× | 18.8×-2.1× | |
| Cash ratio | 3.2×+1.1× | 2.1×-1.2× | 3.3×-8.3× | 11.6×-8.6× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Per Share | |||||
| Book value per share | $2.27-25.9% | $3.06-46.3% | $5.70-12.7% | $6.53-77.9% | |
| Valuation | |||||
| Market capitalization | $709.23M+89.4% | $410.6M-5.9% | $436.44M+12.2% | $388.92M-21.6% | |
| Enterprise value | $641.43M+80.8% | $397.68M-4.2% | $414.94M+44.0% | $288.19M-17.2% | |
| Price / book | 6.6×+3.7× | 2.7×+0.8× | 1.9×-0.1× | 2×-1.3× | |
| Free cash flow yield | -12.9%+8.5pp | -19.7%-4.9pp | -14.8%-0.5pp | -14.3%-7.4pp | |
| Earnings yield | -15.8%+9.4pp | -21.2%-3.7pp | -17.5%-2.4pp | -15.1%-8.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Aura Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Aura Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.